Disc Medicine, Inc. announced its plans for 2025, highlighting key developments in its clinical programs focused on hematologic diseases. The company will discuss plans for NDA submission of ...

The biologics center director reportedly became personally involved after the team reviewing the rare blood disorder filing asked for an extension to the CNPV-accelerated timeline.

The stock of Disc Medicine, Inc. has almost completely recovered from the shares getting cut in half last spring. This clinical staged company is advancing several candidates in its pipeline, ...

WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on developing treatments for rare hematologic diseases, has been making significant strides in its pipeline development.

Disc Medicine has announced a US Food and Drug Administration (FDA) agreement on the regulatory path for its investigational drug bitopertin in treating the rare skin condition erythropoietic ...